AZN

US FDA extends review of AstraZeneca's experimental breast cancer pill

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026